Genetic silencing of pacemaker cells: local intervention with global implications.
作者信息
Karam Caline S, Akar Fadi G
机构信息
Cardiovascular Institute, Mount Sinai School of Medicine New York, NY.
出版信息
J Am Heart Assoc. 2012 Apr;1(2):e001412. doi: 10.1161/JAHA.112.001412. Epub 2012 Apr 24.
Abstract
摘要
相似文献
1
Genetic silencing of pacemaker cells: local intervention with global implications.
J Am Heart Assoc. 2012 Apr;1(2):e001412. doi: 10.1161/JAHA.112.001412. Epub 2012 Apr 24.
2
Risk-benefit assessment of ivabradine in the treatment of chronic heart failure.
Drug Healthc Patient Saf. 2014 Apr 28;6:47-54. doi: 10.2147/DHPS.S43275. eCollection 2014.
3
The Use and Indication of Ivabradine in Heart Failure.
Heart Fail Clin. 2018 Oct;14(4):493-500. doi: 10.1016/j.hfc.2018.06.001. Epub 2018 Aug 18.
4
Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
Drugs. 2004;64(16):1757-65. doi: 10.2165/00003495-200464160-00003.
5
Advances in the management of heart failure: the role of ivabradine.
Vasc Health Risk Manag. 2016 Nov 17;12:453-470. doi: 10.2147/VHRM.S90383. eCollection 2016.
6
Ivabradine for Uncontrolled Sinus Tachycardia in Thyrotoxic Cardiomyopathy - Case Report.
Endocr Metab Immune Disord Drug Targets. 2023;23(7):992-995. doi: 10.2174/1871530323666221214141205.
7
Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20.
8
Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Am J Cardiovasc Drugs. 2012 Dec 1;12(6):415-26. doi: 10.2165/11209990-000000000-00000.
9
Ivabradine for the Treatment of Cardiovascular Diseases.
Circ J. 2019 Jan 25;83(2):252-260. doi: 10.1253/circj.CJ-18-1184. Epub 2018 Dec 29.
10
Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets.
Curr Med Chem. 2011;18(24):3662-74. doi: 10.2174/092986711796642427.
本文引用的文献
1
Biological Heart Rate Reduction Through Genetic Suppression of Gα(s) Protein in the Sinoatrial Node.
J Am Heart Assoc. 2012 Apr;1(2). doi: 10.1161/JAHA.111.000372. Epub 2012 Apr 24.
2
Heart failure: SHIFT shows reversal of left ventricular remodeling with ivabradine.
Nat Rev Cardiol. 2011 Sep 13;8(11):609. doi: 10.1038/nrcardio.2011.141.
3
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
Eur Heart J. 2011 Oct;32(19):2395-404. doi: 10.1093/eurheartj/ehr343. Epub 2011 Aug 29.
4
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Eur Heart J. 2011 Oct;32(20):2507-15. doi: 10.1093/eurheartj/ehr311. Epub 2011 Aug 29.
5
The road to biological pacing.
Nat Rev Cardiol. 2011 Aug 16;8(11):656-66. doi: 10.1038/nrcardio.2011.120.
6
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Lancet. 2010 Sep 11;376(9744):886-94. doi: 10.1016/S0140-6736(10)61259-7.
7
Molecular basis of funny current (If) in normal and failing human heart.
J Mol Cell Cardiol. 2008 Aug;45(2):289-99. doi: 10.1016/j.yjmcc.2008.04.013. Epub 2008 May 11.
8
HCN212-channel biological pacemakers manifesting ventricular tachyarrhythmias are responsive to treatment with I(f) blockade.
Heart Rhythm. 2008 Feb;5(2):282-8. doi: 10.1016/j.hrthm.2007.09.028. Epub 2007 Oct 3.
9
Biological pacemakers based on I(f).
Med Biol Eng Comput. 2007 Feb;45(2):157-66. doi: 10.1007/s11517-006-0060-2. Epub 2006 May 31.
10
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure.
Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1223-30. doi: 10.1152/ajpheart.00079.2007. Epub 2007 Apr 13.
Zotero 插件